Gilead Sciences, Inc., (Nasdaq NASDAQ:), announced that the U.S. Food and Drug Administration had lifted its partial clinical stay on its studies investigating magrolimab and azacitidine combination in myelodysplastic Syndrome (MDS) and acute Myeloid Leukemia (AML) after reviewing the safety data for each study.

Merdad Parsey MD, Ph.D., Chief Medical Officer at Gilead Sciences stated, “This is an important milestone for Gilead as well as for patients with these types of cancers.”

GILD shares are currently down 15% for the year.